
New fish species discovered in Brahmaputra named after Assam's Dibrugarh
One of its most unique features is an incomplete lateral line, a sensory organ that helps fish detect movement and vibrations in the water. It also has a black spot near the tail, which stretches slightly upward and downward along the body.Other distinguishing features include the presence of 10 scales around the tail area, and specific scale patterns on the body — including 4 rows of scales between the dorsal fin and the lateral line, and 4 rows between the lateral line and the pelvic fin.The fish also lacks barbels, the whisker-like structures near the mouth found in many other species, and shows no humeral mark, which is a dark spot near the shoulder area common in other related fish.The discovery adds to the growing list of unique species found in the biodiverse waters of Assam and northeastern India, which are home to many endemic freshwater fish.The researchers behind the study say this new species highlights the ecological richness of the Brahmaputra River system and the urgent need to conserve it.Experts say that detailed scientific studies like these help us better understand freshwater ecosystems and protect lesser-known species from threats such as habitat destruction and pollution.As India continues to explore and catalogue its rich aquatic life, discoveries like Pethia dibrugarhensis remind us of how much there still is to learn — and protect — beneath the surface of our rivers.- Ends

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Trump news at a glance: president goes on offensive over NFL and MBL team names
Donald Trump has weighed into a new fight – this time with two sports teams. The president wants Washington's football franchise the Commanders and Cleveland baseball team the Guardians to revert to their former names, which were abandoned in recent years due to being racially insensitive to Native Americans. Trump said on Sunday on Truth Social that: 'The Washington 'Whatever's' should IMMEDIATELY change their name back to the Washington Redskins Football Team …. Likewise, the Cleveland Indians, one of the six original baseball teams, with a storied past.' Josh Harris, whose group bought the Commanders in 2023, said earlier this year the name was here to stay. The Guardians' president of baseball operations, Chris Antonetti, indicated before Sunday's game against the Athletics that there weren't any plans to revisit the name change. Trump demands Guardians and Commanders change names Donald Trump has said that he would move to block the Commanders' plans to build a new stadium at the old RFK Stadium site in Washington DC unless they changed their name. It is unclear if Trump would be able to do so. The RFK Stadium site was once on federal land but Joe Biden signed a bill earlier this year – one of his final acts in office – transferring control to the DC city government for a 99-year term. Trump also posted that the call to change names applied to Cleveland's baseball team, which he called 'one of the six original baseball teams'. Read the full story Ice secretly deports man, 82, from Pennsylvania An 82-year-old man in Pennsylvania was secretly deported to Guatemala after visiting an immigration office last month to replace his lost green card, according to his family, who have not heard from him since and were initially told he was dead. According to Morning Call, which first reported the story, longtime Allentown resident Luis Leon – who was granted political asylum in the US in 1987 after being tortured under the regime of the Chilean dictator Augusto Pinochet – lost his wallet containing the physical card that confirmed his legal residency. He and his wife booked an appointment to get it replaced and when he arrived at the office on 20 June he was handcuffed by two Immigration and Customs Enforcement (Ice) officers, who led him away from his wife without explanation, she said. The family said they made efforts to find any information on his whereabouts but learned nothing. Read the full story Ice chief says he will continue to allow agents to wear masks The head of US Immigration and Customs Enforcement (Ice) said on Sunday he would keep allowing the controversial practice of his officers wearing masks over their faces during their arrest raids. As Trump has ramped up his unprecedented effort to deport immigrants around the country, Ice officers have become notorious for wearing masks to approach and detain people, often with force. Legal advocates and attorneys general have argued that it poses accountability issues and contributes to a climate of fear. Read the full story US scientists describe impact of Trump cuts Scores of scientists conducting vital research across a range of fields from infectious diseases, robotics and education to computer science and the climate crisis have responded to a Guardian online callout to share their experiences about the impact of the Trump administration's cuts to science funding. Many said they had already had funding slashed or programs terminated, while others feared that cuts were inevitable and were beginning to search for alternative work, either overseas or outside science. So far the cuts have led to a 60% reduction in Johnson's team, and fear is mounting over the future of 30 years of climate data and expertise as communities across the US are battered by increasingly destructive extreme weather events. Read the full story Trump fossil-fuel push setting back green progress decades, critics warn Ever since Donald Trump began his second presidency, he has used an 'invented' national energy emergency to help justify expanding oil, gas and coal while slashing green energy – despite years of scientific evidence that burning fossil fuels has contributed significantly to climate change, say scholars and watchdogs. It's an agenda that in only its first six months has put back environmental progress by decades, they say. Read the full story What else happened today: Trump said he would help Afghans detained in the United Arab Emirates for years after fleeing their country when the US pulled out and the Taliban took power. Polls released on Sunday showed falling support among Americans for Trump's hardline measures against illegal immigration, as the Republican president celebrated six months back in power. Polls from CNN and CBS show Trump has lost majority support for his deportation approach. A growing group of African Americans are ditching corporate big-box retail stores that rolled back their DEI programs and instead are shopping at small, minority- and women-owned businesses they believe value their dollars more. Catching up? Here's what happened on 19 July.
Yahoo
17 minutes ago
- Yahoo
Fun for everyone: Tampa Bay Sun Foundation hosts first "Pros and Pals" event
The "Pros and Pals" event is geared towards making soccer more accessible for children who have physical or sensory disabilities
Yahoo
17 minutes ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data